Consent in flux: when brain‑computer interface embodiment undermines informed consent

Area of Science:

• Neuroscience and Bioethics
• Medical Technology Ethics
• Human-Computer Interaction

Background:

• China approved the first invasive brain-computer interface (BCI) for clinical use globally in March 2026.
• Long-term invasive BCI use raises ethical concerns regarding initial consent for device explantation.
• Participants may develop functional dependence or phenomenological incorporation of BCIs over time.

Purpose of the Study:

• To examine if post-implantation integration weakens the moral authority of initial consent for BCI explantation.
• To analyze the ethical implications of long-term BCI use on embodied agency and the right to withdraw.
• To address a neglected ethical problem in neurotechnology translation.

Main Methods:

• Normative analysis using established bioethics concepts.
• Drawing on theories of extended cognition and transformative experience.
• Integrating qualitative BCI user phenomenology and neurorights discourse.

Main Results:

• Transformative experience alone does not distinguish BCIs from other medical interventions.
• The diachronic consent problem arises from ignorance, extended cognition, and embodied agency.
• China's guidelines have a governance gap; three reforms are proposed: dynamic consent, ongoing ethical review, and decoupling withdrawal from explantation.

Conclusions:

• Informed consent for invasive BCIs should be an ongoing process, not a one-time event.
• Reassessment is necessary when functional dependence or phenomenological incorporation occurs.
• Initial consent should not conclusively authorize explantation without post-integration review.